To review the association of pregnancy with the risk of subsequent development of rheumatic autoimmune diseases in women, including rheumatoid arthritis (RA), systemic lupus erythematosus, and scleroderma.
INTRODUCTION
Autoimmune diseases (AIDs) in general affect women at a disproportionately higher rate than men [1] . The majority of rheumatic AIDs such as systemic lupus erythematosus (SLE), scleroderma [systemic sclerosis (SSc)], and rheumatoid arthritis (RA) are far more prevalent among women. For example, recent population-based incidence and prevalence estimates for SLE reveal that the disease affects women at a rate of 9 : 1 compared with men [2 & ]. Furthermore, the peak incidence of these diseases is well into the menopausal transition, suggesting that in addition to female sex, events over the course of a women's reproductive history likely contribute to disease expression [3] [4] [5] [6] . The immunological effects of sex hormones including estrogen, progesterone, and other pregnancy and postpartum related hormones may have significant roles as epigenetic modifiers in the induction and elaboration of autoimmunity in a susceptible host. As such, reproductive history, including age of menarche, pregnancies, oral contraceptive use, and development of menopause play complex roles in AIDs and continue to be the focus of extensive research. This review covers the current research related to pregnancy and the development of rheumatic AIDs in women ( 
PREGNANCY AND AUTOIMMUNITY
It is useful to examine the AIDs as a group in order to appreciate patterns that may not be discernable when these diseases, many of which are individually rare, are considered as separate entities.
Autoimmune diseases as a group
Certain combinations of autoimmune diseases have been demonstrated to cluster among individuals and within families, supporting the premise of shared environmental and genetic risk factors across AIDs.
A population-based study [7] from Denmark including 1 035 639 women born between 1960 and 1992 examined the development of AID following first pregnancies, including following pregnancies terminated by induced abortion. Their composite AID outcome included a group of 30 well recognized AIDs. During the overall follow-up period, future risk of AID was significantly lower in women who had a first pregnancy that ended with vaginal delivery, compared with nulliparous women, after adjusting for confounders including maternal age and calendar year [relative risk (RR) 0.91; 95% confidence interval (CI) 0.84-0.99]. No association was detected for the overall follow-up interval among women whose first pregnancy ended with cesarean section or induced abortion. When dividing the follow-up interval according to the length of time since the end of pregnancy, a more nuanced pattern emerged. In the first year of follow-up after pregnancy, in comparison with nulliparous women, the risk of AID was significantly increased among women with either vaginal or cesarean deliveries (RR 1.15; 95% CI 1.03-1.28 and RR 1.30; 95% CI 1.10-1.55, respectively), but risk significantly decreased in the year following induced abortion (RR 0.70; 95% CI 0.56-0.88). In contrast, from 12 months onward following the end of first pregnancy, there was a trend toward reduced risk of future AID for women with a vaginal delivery (RRs ranging from 0.84 to 0.95, but only reaching statistical significance for the 3-10 year postpregnancy interval) and no association from 12 months onward for women with cesarean delivery or induced abortion. A significant limitation of this study was that only the first, but not subsequent pregnancies, was analyzed. Thus, the potential cumulative effects of number and timing of pregnancies among multiparous women could not be assessed. However, the results of this study highlight the complexity of the issue of pregnancy and risk of AID, and are compatible with anecdotal evidence that the postpartum year is a specialized window of susceptibility.
A complementary Danish study [8 && ], examining a similar group of 31 AIDs among persons born from 1935 to 1993, examined the number of live births in association with AID. They further grouped AIDs according to those that were female predominant, defined as having a female-to-male ratio of greater than two in the general Danish population, and those that did not meet this definition of female predominance. They found that compared with nulliparous women, women with at least one liveborn child had an increased risk of developing a female-predominant AID, after adjusting for confounders (RR 1.07; 95% CI 1.04-1.10), though when assessing the number of births, this trend only remained significant for women with one live birth and women with four or more live births. For women with two or three live births, the risk of female-predominant disease was similar to that for nulliparous women. Conversely, when assessing the other (nonfemale predominant) AIDs, the risk of disease was reduced for women with at least one child (RR 0.94; 95% CI 0.91-0.97) and was likewise significantly reduced for women with two, three, or more than four live births (RRs ranging from 0.88 to 0.92) compared with nulliparous women. Curiously, for both female-predominant and other AIDs, the patterns observed among women were similar among men who had fathered children, leading to the speculation that there may be sociodemographic or lifestyle factors involved rather than direct biologic effects of pregnancy. Further analyses based on individual AIDs revealed that for six diseases, there were significant associations between parity and risk of disease among women but not men (reduced risk of SLE, and increased risk of Hashimoto thyroiditis, Graves' disease, erythema nodosum, psoriasis, and sarcoidosis), making the case for an association between pregnancy and future risk of disease most compelling for this subset of autoimmune disorders.
Rheumatoid arthritis
RA, a systemic AID associated with symmetric small joint inflammatory arthritis and characteristic autoantibodies (rheumatoid factor and antibodies
KEY POINTS
In general, there remains conflicting evidence regarding an association between pregnancy and risk of rheumatic autoimmune diseases.
Certain autoimmune diseases seem to be more likely than others to be associated with pregnancy based on the large registry studies.
To advance the understanding of the true role of pregnancy in the risk of autoimmune diseases and to clarify windows of vulnerability such as during the postpartum year, detailed assessment is needed of the reproductive factors across the lifespan, in conjunction with the genetic factors and environmental exposures. against citrullinated proteins) [37, 38] , is two to three times more prevalent in women than men [39] . A significant improvement in RA symptoms has been well described during pregnancy in as many as 75% of patients, with subsequent flare in disease often occurring 2-3 months postpartum [40] . In general, this is attributed in part to the shift during pregnancy from a Th-1 to Th2 anti-inflammatory cytokine milieu induced by increased levels of estrogen, progesterone, and cortisol [40, 41] . Thus, much interest has focused on whether pregnancy affects a women's subsequent risk of developing RA. Several retrospective and prospective case-control studies [9, 10, 12, 13] have found a decreased risk of RA among women who had ever been pregnant compared with nulliparous women. One such study [12] from the UK reported the results of a health questionnaire sent to 270 women with RA aged 35-70, 292 osteoarthritis controls, and 245 population-based controls. Information about RA diagnosis date and other medical history was obtained from the records and from patient report. The percentage of nulliparous women was found to be significantly higher in the RA group than in the osteoarthritis or population control groups (26.3 vs. 17.8 and 13.5% respectively; P < 0.05). Adjusted odds ratio (OR) for developing RA was higher in this population for nulliparous women in comparison with both osteoarthritis controls (OR 1.82; 95% CI 1.09-3.03) and population controls (OR 1.83; 95% CI 1.03-3.26). Other risk factors for RA were assessed, including Human Leukocyte antigen (HLA)-DR4 antigen, family history of RA, or use of oral contraceptives, and were not found to be associated with subsequent risk of developing RA. There was a trend toward further risk reduction among women with multiple pregnancies vs. only one or two pregnancies, and a trend toward decreased RA risk with younger age at first pregnancy, which was significant when adjusted for year of birth (P < 0.005). These findings are supported by a similar retrospective case-control study [10] from the Netherlands, in which reproductive history questionnaire data and historical records were also compared in 135 women with RA and 378 controls with osteoarthritis or softtissue rheumatism. A lower OR of developing RA was seen among parous and multiparous women vs. controls (OR 0.53; 95% CI 0.28-0.99).
Another large U.S. population-based prospective case-control study [13] of women aged 18-64 enrolled in a large health plan also found association between pregnancy and RA risk among patients. In this study, the date and the diagnosis of RA for 301 cases were confirmed by board-certified rheumatologists via physical exams and abstraction of records, and RA-specific HLA genotyping of RA cases was performed. A total of 1418 controls were selected randomly from the health plan database. Compared with nulliparous women in the study, parity of any number was significantly associated with a lower RA risk (adjusted RR 0.61; 95% CI 0.43-0.86; P ¼ 0.005). Interestingly, gravidity without parity was not associated with a decreased risk for RA. The risk was lowest among women 1-5 years from their last birth, but risk reduction lessened as time elapsed from last birth. Risk reduction imparted by parity was also not observed in women 45 years and older, nor was RA risk significantly associated with age at first birth or with total number of births. Additionally, among RA cases with two copies of RA-associated HLA alleles, significantly fewer were parous vs. nulliparous (P ¼ 0.02). In a follow-up study [42] involving these 310 RA cases and 571 different controls, for whom HLA genotyping was available, the investigators found relationships between women's parity and HLA genotype, raising the question of whether HLA disparate fetal microchimerism in pregnancy may be affecting the risk. Furthermore, among RA cases with two copies of the HLA alleles, 18% were parous vs. 29% nulliparous, and those negative for the allele 36% were parous vs. 27% nulliparous (P ¼ 0.02), supporting the authors' hypothesis that parity is especially beneficial for women at greatest genetic risk for RA.
Follow-up studies in this study population also revealed an association between complicated pregnancies, in particular delivery of extremely low birth weight infant (ELBW), and subsequent risk of maternal RA (RR 3.7; 95% CI 1.0-12.2) [15 & ]. Other studies, including a Danish national cohort study [16] , have also found association between pregnancy complications and increased RA risk, including hyperemesis (RR 1.70; 95% CI 1.06-2.54), gestational hypertension (RR 1.49; 95% CI 1.06-2.2), and preeclampsia (RR 1.42; 95% CI 1.08-1.84). Unlike the previously cited casecontrol studies, these authors found no association between nulliparity and RA risk in their study population comprising 7017 women and 3041 men with RA admitted to hospital from 1977 to 2004. These authors did, however, note that compared with one-child mothers, women with two or three children were at reduced RA risk (RR 0.84; 95% CI 0.78-0.90 and RR 0.83; 95% CI 0.77-0.91, respectively). Younger age at the birth of the first child was inversely associated with the risk of RA in both women and men (P for trend <0.001), raising the question of environmental, socioeconomic, or epigenetic factors playing a role in clinical disease manifestation. Another large cohort study using prospectively collected data from the Nurses' Health Study [17] found no association between parity and the development of RA, nor an association with the age at first child's birth among 217 incident cases of RA from 1976 to 1982. A subsequent 2004 Nurses' Health Study analysis, reflecting a longer follow-up period, included 674 incident cases of self-reported RA among women followed from 1976 to 2002. Neither parity nor age at first birth was associated with subsequent development of RA in this study [18] . Furthermore, a study [19] of incident cases of RA among a large Finnish cohort found parity increased, not decreased, RA risk among 176 seropositive and 93 seronegative RA cases identified. Compared to nulliparous women, the age-adjusted RR of parous women in this study who went on to develop rheumatoid factor-positive RA was 1.26 (95% CI 0.82-1.92). In general, these and other population-based cohort studies [20, 21] have not found association between pregnancy or parity and risk of RA that has been observed with more frequency in case-control studies as described above, possibly reflecting the differences in study methodology, including heterogeneity of case ascertainment methods and the definition of outcome measures (e.g. pregnancies vs. parity).
Systemic lupus erythematosus
SLE, an antibody-mediated AID characterized by heterogeneous manifestations, is associated with a higher obstetric risk, in particular among those women with active disease or with associated antiphospholipid antibodies [22] . Whether parity increases the risk of SLE is currently unknown, as high-quality studies on large datasets have produced conflicting results. One large population-based Danish cohort study [43] identified 1614 women through a health registry with an ICD-9 diagnosis of SLE and found that women with one or more child had a 25% reduced risk of SLE compared with those who were nulliparous (RR 0.74; 95% CI 0.64-0.86). The risk of developing SLE decreased further for women with two or more children. Increased SLE risk in this study was observed for women with idiopathic pregnancy losses, perhaps reflecting early, preclinical immunologic derangement that would ultimately result in clinical SLE. As referenced in the section on AIDs in general, another Danish study [8 && ] found SLE to be one of six AIDs for which having at least one child was significantly associated with reduced risk among women (RR 0.76; 95% CI 0.66-0.88), but not men. Moreover, the reduced risk of SLE was most pronounced in the year following most recent birth, in which odds of SLE were reduced by 30% compared with 10-14 years after childbirth (OR 0.69; 95% CI 0.52-0.92).
Another population-based case-control study [23] of hormonal effects in 240 SLE patients compared with 321 controls from the Carolina Lupus Study collected data on the reproductive historical events prior to SLE diagnosis, and found no association between the risk of developing SLE and parity, including both live births and number of pregnancies. Similarly, data on 262 incident cases of SLE from the Nurses' Health Study found no association between parity or age at first birth and subsequent development of SLE [26] . Smaller case-control studies [27, 29] of SLE patients identified through record reviews have not demonstrated an association between parity and subsequent development of SLE.
Scleroderma (systemic sclerosis)
SSc is another rheumatic AID with clear female preponderance, with a female-to-male ratio of 4.6 : 1 based on the prevalence data [3] . SSc is characterized by diffuse fibrotic skin changes and vasculopathy, with excess morbidity and mortality associated with cardiopulmonary, renal and gastrointestinal manifestation. The risk of developing scleroderma peaks after the reproductive years in women, with peak incidence during the 45-54 years age range among black women and 65-74 years among white women [3] .
Several studies have examined the question of whether pregnancy is associated with future risk of developing SSc, with conflicting results. Prior pregnancy was reported to be associated with a reduced risk of SSc in two European studies. The first was an Italian study [31] including 46 cases and 153 controls: when adjusted for age, parous compared with nulliparous women had a reduced risk of scleroderma (RR 0.3; 95% CI 0.1-0.8), which on further examination pertained only to women with two or more children. The overall history of any pregnancy, including completed and abortive pregnancies, was associated with a reduced risk of SSc after adjusting for age (OR 0.3; 95% CI 0.1-0.7). The inverse association persisted when also including women with a history of abortive pregnancy. The second study finding an inverse association between parity and SSc was a Swedish study of including 2149 SSc cases and 9879 matched controls born between 1964 and 1999. Results from this case-control study [33] were that nulliparous women had an increased risk of scleroderma (OR 1.37; 95% CI 1.22-1.55), with risk decreasing with increased number of live births.
In contrast, a U.S. study, including 172 SSc cases and 256 non-SSc cases sister controls, found suggestion of a positive association between a history of one or more pregnancies and SSc (OR 2.8; 95% CI not reported). In a subset of 39 cases and 40 unaffected cases sisters, history of at least one live birth and at least one pregnancy loss was reported to be associated with SSc (OR 3.27; 95% CI 1.62-6.6) [34] . An Australian study [36 & ], including 387 SSc cases and 457 controls, found that although SSc cases were more likely to be multiparous compared with controls (OR 1.8; 95% CI 1.1-2.98), there were neither significant differences in number of pregnancies nor age of first pregnancy between cases and controls. Finally, the largest study assessing the pregnancy and risk of SSc was one of the population-based Danish studies cited previously. This study [8 && ] found no evidence for an association with SSc among women with at least one child compared with nulliparous women, after adjusting for confounders (RR 0.90; 95% CI 0.71-1.15).
CONCLUSION
Current literature regarding pregnancy as a risk factor for rheumatic AIDs is conflicting. This may in part reflect the difficulty of case ascertainment and validation of rheumatic diseases, and the challenges of identifying date of disease onset, which is subject to recall bias. The existing studies are furthermore not uniform in how reproductive status was assessed, including whether the outcome of interest was parity or pregnancy, and whether the use of exogenous hormones and family planning issues were considered.
